Global Generic Drugs Market 2014-2018 -





TechNavio's analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market.

 
TechNavio's report, the Global Generic Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas, and the EMEA and APAC regions; it also covers the Global Generic Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

 
Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd.

 
Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd.

 
Key questions answered in this report:

 
What will the market size and growth rate be in 2018?

 
What are the key market trends?

 
What is driving this market?

 
What are the challenges to market growth?

 
Who are the key vendors in this market space?

 
What are the market opportunities and threats faced by key vendors?

 
What are the strengths and weaknesses of each of these key vendors?

 

 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Generic Drugs Market in the US

06.3.1 Market Size and Forecast

06.4 Generic Drugs Market in Europe

06.4.1 Market Size and Forecast

06.5 Generic Drugs Market in Germany

06.5.1 Market Size and Forecast

06.6 Generic Drugs Market in the UK

06.6.1 Market Size and Forecast

06.7 Generic Drugs Market in Italy

06.7.1 Market Size and Forecast

06.8 Generic Drugs Market in France

06.8.1 Market Size and Forecast

06.9 Generic Drugs Market in Spain

06.9.1 Market Size and Forecast

06.10 Generic Drugs Market in China

06.10.1 Market Size and Forecast

06.11 Generic Drugs Market in India

06.11.1 Market Size and Forecast

06.12 Generic Drugs Market in Australia

06.12.1 Market Size and Forecast

06.13 Five Forces Analysis

07. Market Segmentation by Category

07.1 Global Generic Drugs Market by Category

07.1.1 Global Biosimilars Market

08. Market Segmentation by Therapeutic Applications

08.1 Global Generic Drugs Market by Therapeutic Applications

09. Geographical Segmentation

09.1 Global Generic Drugs Market by Geographical Segmentation

09.2 Generic Drugs Market in Americas

09.2.1 Market Size and Forecast

09.3 Generic Drugs Market in the EMEA Region

09.3.1 Market Size and Forecast

09.4 Generic Drugs Market in the APAC Region

09.4.1 Market Size and Forecast

10. Key Leading Countries

The US

China

India

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Actavis plc

19.1.1 Business Overview

19.1.2 Business Segmentation

19.1.3 Key Information

19.1.4 SWOT Analysis

19.2 Mylan Inc.

19.2.1 Business Overview

19.2.2 Business Segmentation

19.2.3 Key Information

19.2.4 SWOT Analysis

19.3 Novartis International AG

19.3.1 Business Overview

19.3.2 Business Segmentation

19.3.3 Key Information

19.3.4 SWOT Analysis

19.4 STADA Arzneimittel AG

19.4.1 Business Overview

19.4.2 Business Segmentation

19.4.3 Key Information

19.5.1 SWOT Analysis

19.6 Teva Pharmaceutical Industries Ltd.

19.6.1 Business Overview

19.6.2 Business Segmentation

19.6.3 Key Information

19.6.4 SWOT Analysis

20. Other Reports in this Series


 


 
List of Exhibits:

Exhibit 1: Market Research Methodology
Exhibit 2: Global Generic Drugs Market Overview
Exhibit 3: Global Generic Drugs Market 2013-2018 (US$ million)
Exhibit 4: Global Generic Drugs Market in the US 2013-2018 (US$ billion)
Exhibit 5: Global Generic Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 6: Generic Drugs Market in Europe Country Wise Market Share 2013
Exhibit 7: Generic Drugs Market in Germany 2013-2018 (US$ billion)
Exhibit 8: Generic Drugs Market in the UK 2013-2018 (US$ billion)
Exhibit 9: Generic Drugs Market in Italy 2013-2018 (US$ billion)
Exhibit 10: Generic Drugs Market in Italy 2013-2018 (US$ billion)
Exhibit 11: Generic Drugs Market in Spain 2013-2018 (US$ billion)
Exhibit 12: Generic Drugs Market in China 2013-2018 (US$ billion)
Exhibit 13: Generic Drugs Market in India 2013-2018 (US$ billion)
Exhibit 14: Generic Drugs Market in Australia 2013-2018 (US$ billion)
Exhibit 15: Global Generic Drugs Market Segmentation
Exhibit 16: Global Biosimilars Market 2013-2018 (US$ million)
Exhibit 17: Global Generic Drugs Market by Therapeutic Applications
Exhibit 18: Global Generic Drugs Market Segmentation by Therapeutic Applications 2013
Exhibit 19: Global Generic Drugs Market by Geographical Segmentation 2013
Exhibit 20: Global Generic Drugs Market in Americas 2013-2018 (US$ billion)
Exhibit 21: Global Generic Drugs Market in Europe 2013-2018 (US$ billion)
Exhibit 22: Generic Drugs Market in China 2013-2018 (US$ billion)
Exhibit 23: Global Generic Drugs Market by Geographical Segmentation 2013-2018 (in percentage)
Exhibit 24: YOY Growth Rate Comparison of the Geographic Segments in the Global Generic Drugs Market 2013-2018
Exhibit 25: Business Segmentation of Actavis plc
Exhibit 26: Business Segmentation of Mylan Inc.
Exhibit 27: Business Segmentation of Novartis International AG
Exhibit 28: Business Segmentation of STADA Arzneimittel AG
Exhibit 29: Business Segmentation of Teva Pharmaceutical Industries Ltd.